Research Article

Airway Epithelial Repair by a Prebiotic Mannan Derived from Saccharomyces cerevisiae

Christie F. Michael,1,2 Christopher M. Waters,3 Kim S. LeMessurier,1,2 Amali E. Samarasinghe,1,2 Chi Y. Song,4 Kafait U. Malik,4 and D. Betty Lew1,2

1Department of Pediatrics, University of Tennessee Health Science Center (UTHSC), Memphis, TN 38103, USA
2Children’s Foundation Research Institute, Le Bonheur Children’s Hospital, Memphis, TN 38103, USA
3Department of Physiology, University of Tennessee Health Science Center (UTHSC), Memphis, TN 38163, USA
4Department of Pharmacology, University of Tennessee Health Science Center (UTHSC), Memphis, TN 38163, USA

Correspondence should be addressed to D. Betty Lew; dlew@uthsc.edu

Received 10 February 2017; Revised 5 May 2017; Accepted 30 May 2017; Published 9 July 2017

Copyright © 2017 Christie F. Michael et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In asthmatic airways, repeated epithelial damage and repair occur. No current therapy directly targets this process. We aimed to determine the effects of mannan derived from S. cerevisiae (SC-MN) on airway epithelial wound repair, in vitro. The presence of functional mannose receptors in bronchial epithelial cells was shown by endocytosis of colloidal gold-Man BSA via clathrin-coated pits in 16HBE cells. In primary normal human bronchial epithelial cells (NHBEC), SC-MN significantly facilitated wound closure. Treatment with SC-MN stimulated cell spreading as indicated by a significant increase in the average lamellipodial width of wound edge 16HBE cells. In addition, NHBEC treated with SC-MN showed increased expression and activation of Krüppel-like factors (KLFs) 4 and 5, transcription factors important in epithelial cell survival and regulation of epithelial-mesenchymal transition. We conclude that SC-MN facilitates wound repair in human bronchial epithelium, involving mannose receptors.

1. Introduction

The hallmarks of asthma exacerbation include inflammation, denudation of the bronchial epithelial barrier, and focal airway damage that is evident on bronchial biopsy even in mild asthmatics [1, 2]. The consequences of repeated epithelial damage and repair are not completely understood, but the disrupted epithelial barrier and epithelial dysfunction are crucial in the development and maintenance of asthma symptoms [3]. This process, triggered by a variety of factors such as ozone [4], radical-containing particles [5], viral infections [6], cigarette smoke [7], and allergens, can ultimately contribute to airway remodeling [3, 7]. Inhaled corticosteroids have been shown to prevent epithelial damage in asthmatics [8]. However, this is likely an indirect result of anti-inflammatory effects rather than a direct protective or repair function. A report by Dorscheid et al. demonstrated that steroid treatment prior to wounding airway epithelial cells in vitro resulted in impairment of both epithelial cell migration and wound closure and induced apoptosis of inflammatory cells and epithelial cells [9]. Indeed, none of the current acute or control therapies for asthma specifically target epithelial integrity or repair. Resolution of airway hyperreactivity (AHR) has been reported to correlate with restoration of the epithelium [1, 10], whereas AHR may persist after resolution of cellular inflammation in human asthma [11].

Moreover, anti-inflammatory therapy alone has not been shown to halt disease progression in asthma [12]. Thus, a therapy that could promote epithelial repair should provide adjunctive therapeutic benefit for asthma.

Mannan, polymannose glycoprotein in the cell wall of various bacterial and fungal species, may have species-specific structure and lipid modifications that regulate the
degree of dendritic cell mannose receptor clustering, differential cytokine profile, and subsequent effector functions [13]. Mannan derived from mycobacteria has been shown to suppress allergic airway disease in a murine-allergic asthma model [14]. On the other hand, mannan derived from pathogenic fungi is likely to induce Th17 inflammatory cytokines [15]. This is in contrast to mannan derived from the outer wall of the commensal yeast Saccharomyces cerevisiae (SC-MN), which does not stimulate Th17 cytokines [15]. However, direct effects of mannan, from any source, on airway epithelium, are unknown. In this study, we show that human bronchial epithelial cells (HBEC) express a functional mannose receptor. We also present evidence that SC-MN facilitates wound healing of bronchial epithelium in vitro, complementary to its antiproliferative effect in airway smooth-muscle cells that we have previously described [16, 17]. At a transcriptional level, we present evidence that SC-MN stimulates expression and activation of Krüppel-like factors (KLFs) 4 and 5, key transcription factors for epithelial cell differentiation, survival, and proliferation [18].

2. Methods

2.1. Cell Cultures. Either primary normal human bronchial epithelial cells (NHBE, Lonza, Walkersville, MD) or an immortalized line of human bronchial epithelial cells, 16HBE (kindly provided by Dr. Gruenert, California Pacific Institute) was cultured either in 6-well plates, in 24-well plates on Transwell inserts with 0.45 μm pores at a liquid/liquid interface, or on 18 mm glass coverslips in 12-well plates to confluence at 37°C and 5% CO₂. The NHBE were cultured in basal epithelial growth media (BEM) supplemented with BulletKit™ (Lonza) at 37°C and 5% CO₂.

2.2. Mannose Uptake Studies. 16HBE cells were grown in on a nylon sheath in Transwell culture plates and were incubated with gold-labeled mannose-bovine serum albumin (10 nm) (ManBSA) or gold-BSA (control) (EY Labs Inc., San Mateo, CA) for 30 min and processed for electron microscopy as we previously described [17].

2.3. Wound Repair Assay. Using a pipette tip (5–200 μl capacity), mechanical wounds were inflicted across the diameter of the wells. Wounded cells were cultured with medium containing 10% fetal bovine serum (HyClone, Logan, UT) and 1% antibiotic/antimycotic solution (Sigma, St. Louis, MO). Cells were incubated with vehicle control (saline, final concentration: 0.005%), SC-MN (0.5–1.0 mg/ml, approximately 14–28 μM) (Sigma, prepared for patented use for asthma therapeutic), budesonide (10⁻⁷ – 10⁻⁹ M), heat-inactivated (50°C, 3 hr) beta-hexosaminidase A (HI-Hex A, endogenous ligand for mannose receptor, 50 nM, microdialyzed to remove ammonium sulfate and stored in 5% glycerin-containing phosphate buffer, Sigma), or a combination of SC-MN and HI-Hex A. Endotoxin levels of these agents were less than 2 EU/ml. Primary NHBE were fixed and stained with crystal violet for overall assessment of wound closure under phase microscopy. Analysis of the perimeter area of the remaining wound in each image was performed using ImageJ software (National Institutes of Health, Bethesda, MD). For lamellipodial analysis, cells were fixed with 3.7% formaldehyde and permeabilized with 0.1% Triton X, followed by staining with rhodamine phalloidin (Molecular Probes, Eugene, OR) according to the manufacturer’s protocol and then images were acquired using fluorescence microscopy [19]. A number of total wound edge cells expressing lamellipodia were counted, and measurements were made using MetaMorph imaging software (version 4.6; Universal Imaging, West Chester, PA).

2.4. Western Blot Analysis. NHBE cell lysates were analyzed for Krüppel-like factors 4 and 5 (KLF4 and KLF5) and phospho-KLF4 and phosphor-KLF5 by Western blot. Protein concentration was determined by Bradford method (Thermo Scientific, Rockford, IL) and 10 μg was loaded per lane for SDS-polyacrylamide gel electrophoresis (8%). Blots of protein bands were probed with primary (KLF4 (rb, 1:500 dilution, EMD Millipore, Billerica, MA); p-KLF4 (Ser245) (rb, 1:500, Abgent, San Diego, CA); KLF5 (rb, 1:500, AVIVA System Biology, San Diego, CA); and p-KLF5 (Ser311) (rb, 1:500, Bio Inc., Woburn, MA; beta-actin (mo, 1:1000, Santa Cruz, Dallas, TX)) and appropriate secondary antibodies and intensity of the bands was measured with ImageJ 1.42 software.

2.5. Statistical Analysis. Data are presented as median +/- SD. Data were analyzed using the nonparametric Kruskal-Wallis one-way analysis of variance test (Graphpad Prism 6, La Jolla, CA). p values less than 0.05 were considered significant.

3. Results

3.1. Presence of Functional Mannose Receptors in Human Epithelial Cells. To assess whether bronchial epithelial cells express mannose receptors, 16HBE cells grown on 24-well Transwell plate inserts were exposed to colloidal gold-Man BSA (10 nm particle size) for 30 min at 37°C. In control experiments, the cells were treated with gold-BESA (Figure 1(a)). Electron microscopic examination of the cells showed gold particles being endocytosed via clathrin-coated pits in 16HBE cells, indicating the presence of functional mannose receptors (Figure 1(b)) [17].

3.2. Facilitation of Repair by SC-MN on Mechanically Inflicted Wounds in HBEC. Mannan from S. cerevisiae enhanced wound closure in primary NHBE. SC-MN-treated cells (1 mg/ml) showed accelerated wound closure compared to the control cultures and budesonide-treated cells (10⁻⁷ M) (Figure 2, images acquired at the 32 hr time point). Budesonide was used for comparison because this inhaled corticosteroid is frequently used to treat asthma in young children. The average number of wound edge cells expressing lamellipodial extensions analyzed at the 24 hr time point under high-power magnification was 5/14 (36%) for untreated controls, 11/11 (100%) for mannan-treated cultures, and 8/14 (57%) for budesonide-treated cultures. Measurements of the remaining wound area at the 32 hr time point are shown in Figure 3. SC-MN (0.5 and 1.0 mg/ml)
significantly facilitated wound closure compared to the control cultures in contrast to the lack of beneficial effect by budesonide treatment.

3.3. Facilitation of Repair by SC-MN on Mechanically Inflicted Wounds in 16HBE. Similar results were obtained in a faster growing 16HBE cells (Figure 3) when wound closure was examined over time. There was no significant difference in closure at 8 hrs, but by 13 hrs, differences became evident. At 17 hours, the SC-MN- or HI-Hex A-treated wounds had 30% or less wound area remaining, versus the 50% or greater remaining for control cultures, respectively (data not shown). Combining SC-MN (1 mg/ml) and HI-Hex A (50 nM) appeared to maximize wound closure (Figure 4). Accelerated 16HBE cell spreading and migration were apparent at the cellular level as early as 8 hrs in all three conditions (mannan treated, HI-Hex A treated, and a combination of these agents), compared to those of control cells. Figure 5 shows images of rhodamine-phalloidin-stained actin. Average lamellipodial width of wound edge cells at 13 hours after wounding was significantly increased in SC-MN-treated (4.47+/− 0.90 microns, n = 10) versus control 16HBE cells (1.57+/− 0.59 microns, n = 6) (p < 0.05), indicating increased spreading and enhanced migration. The overall appearance of the wound edge cells in the HI-Hex A or SC-MN-treated groups was consistent with an active healing process not only by lamellipodial extensions but also by directionality toward the opposing wound edge (Figure 5).
3.4. Effect of SC-MN on KLF4 and KLF5 Expression and Activation in NHBE Cells. Although mannose receptor (MR) activation in airway smooth muscle cells is known to involve signal transduction pathways including transient elevation of cAMP [20], PKC activation [21], and ERK1/2 activation [22], the mechanism by which SC-MN affects epithelial repair is unknown. To gain insight into postreceptor mechanisms at the transcriptional level, we assessed whether the reparative effects of SC-MN on airway epithelial cells involved transcriptional factors KLF4 or KLF5, which are known to be associated with cell differentiation, survival, and proliferation [18]. Mannan from *S. cerevisiae* (1 mg/ml) stimulated the expression and phosphorylation of KLF4 and KLF5 (Figure 6) at 2–18 hr time points in NHBEC.

4. Discussion

We present evidence that a functional MR family member is expressed in human bronchial epithelial cells; this is supported by endocytosis of mannosylated neoglycoprotein in clathrin-coated pits. This adds to the list of MR in the epithelium: retinal pigment epithelial cells [23] and nasal polyposis [24]. In search of a therapeutic that can directly impact the epithelial damage occurring in asthma, we have discovered that SC-MN facilitates healing of human bronchial epithelial wounds in vitro. The healing effect of SC-MN on primary NHBEC was significant compared to that of the control cells and contrasted to budesonide (glucocorticosteroids) treatment which did not improve wound healing. Asthma
research on beta-hexosaminidases (Hex A and Hex B), endogenous enzymes, and known ligands for mannose receptors, has been hampered by the lack of highly purified enzyme (the preparation used for our previous work was 150–170 times more pure compared to the commercially available beta-hexosaminidases) [16]. Nevertheless, heat-inactivated Hex A, produced a similar healing effect on airway epithelium, further supporting the presence of a mannose receptor in human bronchial epithelium.

Epithelial repair mechanisms involve cell migration and proliferation, promoted by multiple growth factors, chemokines (MCP-1), cytokines (IL-1β, IL-2, IL-4, and IL-13), and prostaglandins (PGE2) that work in coordination with integrins and other matrix materials (fibronectin, collagen, and laminin) [25]. Treatment of bronchial epithelial cells with SC-MN does not produce the abovementioned cytokines (preliminary unpublished data). Many cellular molecular factors, such as Sonic hedgehog, Rho GTPases, MAP kinase pathways, STAT3, and Wnt [25], contribute to epithelial cell migration and proliferation. In addition to promoting wound closure, SC-MN appears capable of initiating directional migration of human bronchial epithelial cells. However, the specific mechanisms of how SC-MN directs epithelial migration and proliferation downstream of MR are unknown.

In order to determine the underlying mechanisms of airway epithelial wound healing by SC-MN, KLF4 and KLF5 expression were determined. These transcription factors are known to be associated with differentiation, survival, and cell proliferation. Within 2 hrs of cell exposure to SC-MN, KLF4 expression and activation (by phosphorylation) were apparent. This association of KLF4 expression and activation is likely a contributing factor to directional migration of epithelial cells during wound closure. SC-MN also induced KLF5 expression and activation in NHBEC at 2–18 hrs (peak at 18 hrs), and KLF5 is known to inhibit epithelial mesenchymal transition by microRNA 200 transcription [26].

There are limitations of this study in respect to cell types and culture system. Primary human bronchial cells from asthmatic patients would have provided further insight to the beneficial effect of mannans in asthma; however, they are extremely difficult to acquire. In addition, the culture of NHBEC in an air-liquid interface model could elucidate mannans’s effect on differentiated cells. Regarding the mechanisms of SC-MN’s action, it is possible that mannans may work through alternative mechanisms in epithelial cells other than a receptor-mediated phenomenon. For example, it may act as a barrier protection as it does in yeast. Another possibility is that endotoxin of SC-MN, even though the concentration is minimal, might have had some influence in epithelial cells.

The mannose receptor and other endogenous glycan-binding proteins, implicated in both innate and adaptive immunity, represent a largely unexplored opportunity to modulate immune responses. Glycoprotein endogenous ligands for MR (β-Hex A and B, aka NAGA (N-Acetyl-β-D-Glucosaminidase), NAG, and NAGase) are elevated in bronchoalveolar lavage fluids of guinea pigs exposed to ozone [4] and in serum of asthmatic patients, more so in severe asthmatics [27]. Moreover, gene variants of glycoprotein and resulting abnormal serum levels of the respective glycoproteins are associated with asthma [28]. Although the specific subtype of mannose receptor expressed in airway bronchial epithelial cells is yet to be determined, sufficient evidence exists to indicate the presence of a functional receptor in the mannose family. SC-MN is an appealing agent with therapeutic potential for repairing wounded bronchial epithelium in addition to its already known effect of antiinflammatory effect in airway smooth muscle cells [16]. We conclude that SC-MN mediates a direct healing effect on human bronchial epithelial cell wounds, in part, by engagement of a mannose receptor. Intricate regulation by SC-MN at the transcriptional level involving KLF4 and KLF5 and their posttranslational modifications (phosphorylation, acetylation, and methylation) needs further investigation.

**Abbreviations**

| Abbreviation | Full Form |
|--------------|-----------|
| EMT          | Epithelial-mesenchymal transition |
| NHBEC        | Normal human bronchial epithelial cells |
| KLF          | Krüppel-like factor |
| ManBSA       | Mannosylated bovine serum albumin |
| OVA          | Ovalbumin |
| SC-MN        | Saccharomyces cerevisiae mannans |
| Hex A        | β-Hexosaminidase A |
| HI           | Heat inactivated |
Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors wish to thank Dr. Kenneth Chapman for his scientific contribution and Julie Chang and Carolyn Stewart for their technical assistance. This work was supported in part by Le Bonheur Foundation (Christopher M. Waters), NIH-HL56812 and NIH-HL090108 (Dr. Betty Lew), University Tennessee Research Foundation-Cumberland Pharmaceuticals & Emerging Technology (Dr. Betty Lew), University of Tennessee Clinical Translational Science Institute (Dr. Betty Lew), NIH-HL123540 and NIH-HL094366 (Christopher M. Waters), and NIH-HL079109 (Kafait U. Malik).

References

[1] J. V. Fahy, "Type 2 inflammation in asthma—present in most, absent in many," Nature Reviews. Immunology, vol. 15, pp. 57–65, 2015.
[2] L. A. Laitinen, A. Laitinen, and T. Haahetla, “Airway mucosal inflammation even in patients with newly diagnosed asthma,” The American Review of Respiratory Disease, vol. 147, pp. 697–704, 1993.
[3] S. T. Holgate, “Mechanisms of asthma and implications for its prevention and treatment: a personal journey,” Allergy, Asthma & Immunology Research, vol. 5, pp. 343–347, 2013.
[4] D. B. Lew, V. Chodimella, and C. G. Murlas, “Guinea pig ozone-induced airway hyperreactivity is associated with increased N-acetyl-beta-D-glucosaminidase activity in bronchoalveolar lavage fluid,” Lung, vol. 166, pp. 273–283, 1990.
[5] P. T. Thevenot, J. Saravia, N. Jin et al., “Radical-containing ultrasound particulate matter initiates epithelial-to-mesenchymal transitions in airway epithelial cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 48, pp. 188–197, 2013.
[6] N. S. Holden, T. George, C. F. Rider et al., “Induction of regulator of G-protein signaling 2 expression by long-acting beta2-adrenoceptor agonists and glucocorticoids in human airway epithelial cells,” The Journal of Pharmacology and Experimental Therapeutics, vol. 348, pp. 12–24, 2014.
[7] E. Veljkovic, J. Jiricny, M. Menigatti, H. Rehrauer, and W. Han, “Chronic exposure to cigarette smoke condensate in vitro induces epithelial to mesenchymal transition-like changes in human bronchial epithelial cells, BEAS-2B,” Toxicology in Vitro, vol. 25, pp. 446–453, 2011.
[8] L. A. Laitinen, A. Laitinen, and T. Haahetla, “A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial,” The Journal of Allergy and Clinical Immunology, vol. 90, pp. 32–42, 1992.
[9] D. R. Dorscheid, B. J. Patchell, O. Estrada, B. Marroquin, R. Tse, and S. R. White, “Effects of corticosteroid-induced apoptosis on airway epithelial wound closure in vitro,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 291, pp. L794–L801, 2006.
[10] P. K. Jeffery, A. J. Wardlaw, F. C. Nelson, J. V. Collins, and A. B. Kay, “Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity,” The American Review of Respiratory Disease, vol. 140, pp. 1745–1753, 1989.
[11] H. H. Kariyawasam, M. Aizen, J. Barkans, D. S. Robinson, and A. B. Kay, “Remodeling and airway hyperresponsiveness but not cellular inflammation persist after allergen challenge in asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 175, pp. 896–904, 2007.
[12] NHLBI issues updated guidelines for the diagnosis and management of asthma,” American Family Physician, vol. 56, pp. 621–623, 1997.
[13] J. Nigou, C. Zelle-Rieser, M. Gilleron, M. Thurnher, and G. Puzo, “Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor,” Journal of Immunology, vol. 166, pp. 7477–7485, 2001.
[14] I. Sayers, W. Severn, C. B. Scanga, J. Hudson, G. Le Gros, and J. L. Harper, “Suppression of allergic airway disease using mycobacterial lipoglycans,” The Journal of Allergy and Clinical Immunology, vol. 114, pp. 302–309, 2004.
[15] L. Rizzetto, M. Kuka, C. De Filippo et al., “Differential IL-17 production and mannann recognition contribute to fungal pathogenicity and commensalism,” Journal of Immunology, vol. 184, pp. 4528–4528, 2010.
[16] D. B. Lew and M. C. Rattazzi, “Mitogenic effect of lysosomal hydrolases on bovine tracheal myocytes in culture,” The Journal of Clinical Investigation, vol. 88, pp. 1969–1975, 1991.
[17] D. B. Lew, E. Songu-Mize, S. E. Pontow, P. D. Stahl, and M. C. Rattazzi, “A mannose receptor mediates mannosyl-rich glycoprotein-induced mitogenesis in bovine airway smooth muscle cells,” The Journal of Clinical Investigation, vol. 94, pp. 1855–1863, 1994.
[18] B. B. McConnell and V. W. Yang, “Mammalian Kruppel-like factors in health and diseases,” Physiological Reviews, vol. 90, pp. 1337–1381, 2010.
[19] L. P. Desai, K. E. Chapman, and C. M. Waters, “Mechanical stretch decreases migration of alveolar epithelial cells through mechanisms involving Rac1 and Tiam1,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 295, pp. L1958–L1965, 2008.
[20] D. B. Lew, C. Nebigil, and K. U. Malik, “Dual regulation by cAMP of beta-hexosaminidase-induced mitogenesis in bovine tracheal myocytes,” American Journal of Respiratory Cell and Molecular Biology, vol. 7, pp. 614–619, 1992.
[21] D. B. Lew, E. R. Brown, B. K. Dempsey, H. M. Wright, and K. U. Malik, “Contribution of PKC to beta-hexosaminidase-induced airway smooth muscle proliferation,” The American Journal of Physiology, vol. 272, pp. L639–L643, 1997.
[22] D. B. Lew, B. K. Dempsey, Y. Zhao, M. Muthalif, S. Fatima, and K. U. Malik, “Beta-hexosaminidase-induced activation of p44/42 mitogen-activated protein kinase is dependent on p21Ras and protein kinase C and mediates bovine airway smooth muscle proliferation,” American Journal of Respiratory Cell and Molecular Biology, vol. 21, pp. 111–118, 1999.
[23] C. J. Greaton, K. B. Lane, V. L. Shepherd, and B. J. McLaughlin, “Transcription of a single mannose receptor gene by macrophage and retinal pigment epithelium,” Ophthalmic Research, vol. 35, pp. 42–47, 2003.
[24] S. Claeyts, T. De Belder, G. Holtappels et al., “Macrophage mannose receptor in chronic sinus disease,” Allergy, vol. 59, pp. 606–612, 2004.
[25] L. M. Crosby and C. M. Waters, “Epithelial repair mechanisms in the lung,” *American Journal of Physiology. Lung Cellular and Molecular Physiology*, vol. 298, pp. L715–L731, 2010.

[26] B. Zhang, Z. Zhang, S. Xia et al., “KLF5 activates microRNA 200 transcription to maintain epithelial characteristics and prevent induced epithelial-mesenchymal transition in epithelial cells,” *Molecular and Cellular Biology*, vol. 33, pp. 4919–4935, 2013.

[27] M. M. Tomasiak, M. Tomasiak, Z. Zietkowski, R. Skiepko, and A. Bodzenta-Lukaszyk, “N-acetyl-beta-hexosaminidase activity in asthma,” *International Archives of Allergy and Immunology*, vol. 146, pp. 133–137, 2008.

[28] S. Sharma, X. Zhou, D. M. Thibault et al., “A genome-wide survey of CD4(+) lymphocyte regulatory genetic variants identifies novel asthma genes,” *The Journal of Allergy and Clinical Immunology*, vol. 134, pp. 1153–1162, 2014.